Immunotherapy rechallenge in patients with non-small-cell lung cancer

Pulmonology. 2020 Jul-Aug;26(4):252-254. doi: 10.1016/j.pulmoe.2020.01.007. Epub 2020 Apr 27.

Authors

S España¹, I Guasch², E Carcereny³

Affiliations

¹ Medical Oncology Service. Catalan Institute of Oncology, Badalona, Spain. Electronic address: sofia.ef@iconcologia.net.
² Radiodiagnostic Service, Hospital Germans Trias i Pujol, Badalona, Spain.
³ Medical Oncology Service. Catalan Institute of Oncology, Badalona, Spain.

PMID: 32354686
DOI: 10.1016/j.pulmoe.2020.01.007

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Administration, Intravenous
Carcinoma, Non-Small-Cell Lung / drug therapy*
Carcinoma, Non-Small-Cell Lung / immunology
Carcinoma, Non-Small-Cell Lung / radiotherapy
Diagnosis, Differential
Disease Progression
Drug Therapy, Combination
Female
Glucocorticoids / administration & dosage
Glucocorticoids / therapeutic use
Humans
Immune Checkpoint Inhibitors / administration & dosage
Immune Checkpoint Inhibitors / adverse effects
Immune Checkpoint Inhibitors / therapeutic use
Lung Neoplasms / pathology*
Middle Aged
Neoadjuvant Therapy / methods
Nivolumab / administration & dosage
Nivolumab / adverse effects*
Nivolumab / therapeutic use
Pneumonia / chemically induced*
Pneumonia / diagnosis
Pneumonia / drug therapy
Prednisolone / administration & dosage
Prednisolone / therapeutic use
Treatment Outcome
Withholding Treatment

Substances

Glucocorticoids
Immune Checkpoint Inhibitors
Nivolumab
Prednisolone